OchsnerHealth

Single-Patient Nurse Mixing Instruction Sheet

Non-24/7 Pharmacies and Free-Standing Emergency Department

levETIRAcetam (Keppra) 15 mg/mL in 0.9% NaCl IV syringe (PEDS)

* Withdrawn from levETIRAcetam (Keppra) 1,500 mg/100 mL 0.9% NaCl premix bag

SUPPLIES *include quantity and medication name, strength/concentration, volume, diluent, diluent volume, and quantity and name of each supply needed*

NS flush syringes are never to be used for reconstitution/diluent for medication.
Reconstituted solution is for single patient use only.

- One (1) levETIRAcetam (Keppra) 1,500 mg/100 mL 0.9% NaCl premix bag
- Alcohol swabs
- One (1) 18-gauge needle preferred (20-23 gauge needles acceptable)
- One (1) appropriate sterile IV syringe size if ordered dose volume is less than or equal to 50 mL
- One (1) empty, sterile IV container 100 mL and one (1) 50 mL sterile IV syringe if ordered dose volume is greater than 50 mL
- Nursing IV admixture label(s) – Lawson # 626

STEPS *explicitly state each step in chronological order, including hand washing, gown/garb, alcohol swab, etc.)*

1. Wash hands. Prepare/clean the designated mixing area.
2. Wipe the injection port of levETIRAcetam (Keppra) 1,500 mg/100 mL 0.9% NaCl premix bag with alcohol swab(s).
3. Label the levETIRAcetam 1,500 mg/100 mL 0.9% NaCl floor stock bag with:
    a. Hang-by date and time (**administration must begin within 1 hour from the time of compounding**)
    b. Initials of person compounding
4. Attach 18 gauge needle to syringe and withdraw patient-specific ordered dose volume from floor stock bag into syringe:
    a. If ordered dose volume is less than or equal to 50 mL, proceed to step 5.
    b. If ordered dose volume is greater than 50 mL, transfer patient-specific ordered dose volume into an empty IV container 100 mL. Wipe the injection port of the empty container prior to transferring dose.
5. Discard the floor stock bag once dose is withdrawn.
6. Visually inspect syringe containing patient-specific dose for particulate matter/defects. Discard if any defects.
7. Label the final IV syringe/IVPB with the following information:
    a. Patient name and location
    b. Drug name, strength, and dose (if not apparent by the container)
    c. Diluent and volume (if not apparent by the container)
    d. Hang-by date and time (**administration must begin within 1 hour from the time of dose withdrawn from floor stock bag**)
    e. Initials of person compounding

References

- levetiracetam injection [prescribing information]. Princeton, NJ: Dr.Reddy's Laboratories Inc. Revised: 7/2022. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0a9234b7-46b1-8e6c-a992-90f86cfb6e00&type=display
- United States Pharmacopeia (USP). General Chapter, <797> Pharmaceutical Compounding—Sterile Preparations. (2023) USP-NF. Rockville, MD: United States Pharmacopeia. https://ochsnerhealth.sharepoint.com/sites/ClinicalResources/SiteAssets/Forms/AllItems.aspx?id=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness%2FUSP%2D797%2DOfficial%2D11%2E1%2E23%2Epdf&parent=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness.